NR 565 Advanced Pharmacology Midterm 2026/2027 – 200+ Questions & Answers | Pharmacokinetics, Opioids, HTN, Cardiovascular Drugs, Gout & DMARDs – NR 565 | Chamberlain University

This comprehensive NR 565 Advanced Pharmacology Midterm 2026/2027 study resource contains 200+ exam-style questions and answers across 51 pages, designed for focused review of advanced pharmacology and safe prescribing principles. The material covers pharmacokinetics and pharmacodynamics, CYP450 drug interactions, pharmacogenomics, prescribing authority, controlled substances, opioid pharmacology, hypertension, cardiovascular medications, anticoagulants, lipid-lowering therapy, gout, osteoporosis, NSAIDs and disease-modifying antirheumatic drugs (DMARDs). It also emphasizes medication selection and monitoring across pregnancy, pediatric and geriatric populations. The opening sections provide extensive preparation in clinical pharmacology and safe prescribing. Topics include CYP450 enzyme induction and inhibition, altered absorption, distribution, metabolism and excretion, therapeutic monitoring, adverse drug reactions, medication adherence, black-box warnings and the Beers Criteria. Special-population pharmacology includes physiological changes during pregnancy, teratogenic medications, neonatal and pediatric drug absorption, weight- and body-surface-area dosing and age-related changes in renal function, hepatic metabolism, body composition and medication clearance. The document also examines the legal and professional responsibilities of advanced practice prescribers, including full, reduced and restricted practice authority, state regulation of prescriptive authority, essential prescription components, NPI and DEA information and clinical considerations when selecting medications. Controlled-substance material reviews DEA Schedules I–V, prescription drug monitoring programs (PDMPs), Schedule II prescribing requirements and opioid-risk assessment. These sections are especially relevant to nurse practitioner students learning how pharmacology intersects with APRN prescribing practice. A substantial section focuses on opioid pharmacology and pain management. Students review morphine, fentanyl, codeine, oxycodone, hydrocodone, methadone, tramadol, buprenorphine and naloxone, along with pure opioid agonists, agonist-antagonists and antagonists. Topics include opioid potency, morphine milligram equivalents (MME), respiratory depression, constipation, tolerance, physical dependence, opioid use disorder, withdrawal, overdose recognition and naloxone administration. The guide also addresses opioid interactions with benzodiazepines, alcohol and other CNS depressants and discusses nonopioid and nonpharmacologic approaches to chronic pain. Another major component covers hypertension, heart failure, angina and cardiovascular pharmacotherapy. Drug classes include thiazide and loop diuretics, ACE inhibitors, ARBs, calcium-channel blockers, beta blockers, aldosterone antagonists and direct vasodilators. Individual medications discussed include lisinopril, losartan, furosemide, spironolactone, eplerenone, aliskiren, nifedipine, verapamil, minoxidil and hydralazine. Students review mechanisms of action, hyperkalemia, hypokalemia, angioedema, cough, ototoxicity, orthostatic hypotension and clinically significant drug interactions. The cardiovascular review further includes digoxin, antiarrhythmics, anticoagulation, lipid management and antianginal therapy. Questions address digoxin monitoring and toxicity, quinidine and amiodarone, warfarin and INR monitoring, nitroglycerin tolerance and PDE-5 inhibitor interactions, beta-blocker withdrawal and ASCVD risk assessment. Lipid-lowering pharmacology includes statins, ezetimibe, fibrates and bile-acid sequestrants, with attention to rhabdomyolysis, hepatotoxicity, CYP3A4 interactions and patient education. The final sections provide targeted preparation in gout, osteoporosis and inflammatory disease pharmacology. Students review NSAIDs, colchicine, allopurinol, febuxostat, alendronate and other bisphosphonates, raloxifene, methotrexate and hydroxychloroquine. Important concepts include acute versus prophylactic gout therapy, severe cutaneous reactions, medication interactions, bisphosphonate administration, esophagitis and osteonecrosis, baseline monitoring for DMARD therapy and pregnancy considerations in rheumatoid arthritis treatment. Relevant students: This document is particularly relevant for NR 565 students, Chamberlain University nursing students, MSN students, Family Nurse Practitioner (FNP) students, nurse practitioner students, advanced practice registered nursing students and graduate nursing students studying advanced pharmacology or preparing for a pharmacology midterm. The question-and-answer format is suitable for active recall, rapid revision, medication-class comparison and identifying weak areas in prescribing, mechanisms, interactions, contraindications and adverse effects. Keywords: NR 565 Advanced Pharmacology, NR 565 midterm , NR 565 midterm questions and answers, NR 565 exam prep, Chamberlain NR 565, Advanced Pharmacology midterm, Advanced Pharmacology questions and answers, nurse practitioner pharmacology, FNP pharmacology, pharmacokinetics, pharmacodynamics, CYP450 inhibitors, CYP450 inducers, Beers Criteria, pharmacogenomics, prescriptive authority, controlled substances, DEA drug schedules, opioid pharmacology, opioid prescribing, naloxone, morphine milligram equivalents, hypertension medications, ACE inhibitors, ARBs, calcium channel blockers, beta blockers, diuretics, heart failure pharmacology, digoxin, antiarrhythmic drugs, warfarin, nitroglycerin, statins, lipid lowering medications, gout pharmacology, colchicine, allopurinol, osteoporosis medications, bisphosphonates, NSAIDs, DMARDs, methotrexate, graduate nursing pharmacology